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After  sensitization  with  an  allograft,  the  mouse  develops  thymus-derived  (T) 
lymphocytes that are selectively cytotoxic for cells bearing donor alloantigens (1, 2). 
Intimate  contact  (3)  between  viable  sensitized  lymphocytes and  target  cells  is  a 
prerequisite  for  cytotoxicity  (lymphocyte-mediated  cytotoxicity  or  LMC)  I  (1-3) 
although the exact nature of the cytotoxic process is unknown. A variety of agents 
that stimulate adenylate cyclase,  the enzyme that catalyzes the formation of adeno- 
sine  3',5'-cyclic  monophosphate  (cyclic  AMP)  from  adenosine  5'-triphosphate 
(ATP), and methylxanthines, which inhibit the hydrolysis of cyclic AMP to 5P-adeno  - 
sine  monophosphate  (5'-AMP),  suppress LMC  mediated  by mouse  (4-6)  and  rat 
(7) cells. Cholinergic agents, which have been shown to elevate intracellular guanosine 
3',5'-cyclic monophosphate (cyclic  GMP)  in  a  variety of tissues  (8-13),  including 
the  human  lymphocyte  (13) through  activation  of  guanylate  cyclase,  enhance 
LMC (7). 
The present studies employing a  purified rat spleen lymphocyte population 
establish  that  the  effects of  activators  of  adenylate  cyclase  and  cholinergic 
agents are mediated by an action upon the attacking and not target cells.  They 
further reveal that cholinergic enhancement is not associated with a measurable 
change in cyclic AMP levels, is duplicated by 8-bromo-cyclic guanosine 3', 5'- 
monophosphate (8-bromo-cyclic GMP), and is independent of the presence of 
immunoglobulin-bearing  lymphocytes.  Finally,  the  results  indicate  that  the 
modulating effects of the intracellular  levels of cyclic AMP  and cyclic GMP 
upon  the  attacking cell population  are  dependent  upon  the  concentration  of 
cyclic  nucleotides  (cyclic  AMP  and  cyclic  GMP)  at  the  moment  of  initial 
interaction with the target cells. 
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Materials and Methods 
The agents listed were obtained from manufacturers: carbamylcholine chloride (carbachol), 
imidazole, aminophylline, and DL-isoproterenol  (Sigma Chemical Co., St. Louis, Mo.); RPMI- 
1640 medium and fetal calf sera (Grand Island Biological Co., Grand Island, N. Y.) ; fluorescein 
isothiocyanate (FITC) and unabsorbed guinea pig complement (C)  (Nutritional Biochemical 
Corp., Cleveland, Ohio); desoxyribonuclease (DNase)  (Pentex Biochemical, Kankakee, Ilk); 
and  Na2[51CrJO4 (specific  activity  =  1  mCi/ml)  (Nuclear-Chicago, Corp.,  Chicago,  Ill.). 
Prostaglandin E1  (PGE1),  cholera toxin, and 8-bromo-cyclic GMP were gifts received from 
Dr.  John Pike,  The  Upjohn Co.,  Kalamazoo, Mich.;  SEATO  Cholera Research Program, 
National Institute of Allergy and Infectious Diseases; and Dr. Lionel Simon of ICN Nuclear 
Acid Research Institute (ICN Corp., Irvine, Calif.), respectively. Male Lewis, Brown Norway 
(BN),  and  (Lewis)<  Brown Norway F1)  (LBN)  rats were obtained from Microbiological 
Associates, Inc., Bethesda, Md. 
Grafting and Cell Preparation.--Lewis  rats were given full-thickness skin grafts, 2.5 cm in 
diameter, from LBN rats. After exsanguination of anesthetized rats by aortic puncture, sensi- 
tized Lewis rat spleen tissue and normal BN thymus tissue were excised and placed in wash 
medium consisting of RPMI-1640  medium containing 0.5  vol  percent of 1 M  buffer (N-2- 
hydroxyethylpiperazine-N'-2-ethanesulfonic  acid)  and 4%  (vol/vol)  heat-inactivated  (56°C 
for 2 h)  fetal calf serum.  The  organs  were  expressed manually  through a  60  gauge  steel 
mesh, and the resulting suspensions passed through a tube containing cotton to remove tissue 
fragments. The spleen and thymus cell preparations were purified by Ficoll-Hypaque gradient 
separation (14) such that the final suspensions consisted of lymphoid cells that appeared 98% 
viable by phase microscopy. After washing twice with sedimentation at 200 g at room tem- 
perature, 1.0 ml of the thymic cell suspension containing 105-107 cells was incubated at 37°C 
ith 400w b~Ci of 51Cr for 1 h. The suspension was then washed twice to remove free alCr.  The 
spleen and thymus cells were suspended in culture medium consisting of RPMI-1640 medium 
to which 10%  (vol/vol) heat-inactivated fetal calf serum and 0.5 vol percent of 1 M  buffer 
were added.  The  number of  thymus and  spleen cells  in  suspension was determined on  a 
Coulter counter (Coulter Electronics, Inc., Hialeah, Fla.).  1 aliquot of spleen cells was used 
for quantitation of LMC and the other was placed in Tyrode's buffer for determination of 
intracellular cyclic AMP levels. 
Quantitation of Lymphocyte-Mediated Cytotoxicity (LMC).--LMC  was  determined  by  a 
modification of the technique of Brunner et al.  (15). The attacking cell population consisted 
of Lewis spleen cells harvested 7 days post-LBN to Lewis grafting, and the target cells were 
51Cr-labeled BN thymocytes. 5 X  104 BN thymocytes were added to 5 )<  106 sensitized Lewis 
spleen cells to achieve a  final  medium vol of 2 ml in triplicate samples placed in disposable 
10  )<  75-mm glass tubes. After incubation at 37°C for 30 min, the mixtures were centrifuged 
at 50 g for 10 min and further incubated for 3.5 h at 37°C. The cells were sedimented at 400 g 
for 10 min and the supernatants were decanted into disposable 13 X  100-ram glass test tubes 
and counted for 51Cr release.  5 >(  104 target cells suspended in 2 ml of culture medium were 
used to determine spontaneous ~lCr release.  Pharmacologic agents diluted in saline just before 
use were interacted with  the sensitized lymphocytes for a  varying  time interval at  room 
temperature before introduction of the target cells.  Parallel cultures of target or attacking 
cells alone were interacted with pharmacologic agents under identical conditions. The pharma- 
cologic agents, in the concentrations reported, did not injure either target or attacking cells 
as determined in SlCr release studies. 2-ml suspensions of 5 X  104 target cells were frozen and 
thawed in a  dry ice-ethanol bath three times to determine maximum releasable cell-bound 
chromium. The percent specific cell lysis was determined as follows: 
VExperimental cpm -- control cpm  7 
Specific cell lysis (%) =  [- Freeze-tha~ c~m -- contro~ c~m .J X  100. STROM, CARPENTER, GAROVO¥, AUSTEN, MEI~RILL~ KALINER  383 
Spleen cells from Lewis rats sensitized with LBN skin grafts do not injure Lewis thymocytes 
and cause only barely detectable injury to Buffalo rat thymocytes (7), whereas the sensitized 
Lewis spleen cell populations used in this study produced 38-46% specific lysis of BN target 
cells. Unsensitized Lewis spleen cells do not injure BN thymocytes (7). 
The percent augmentation or suppression of specific lysis noted with pharmacologic  treat- 
ment was determined as follows: 
% change (all data expressed as positive values) 
I%  specific lysis in treated mixture  1 
=  % specific lysis in untreated mixture )< 100  -  100. 
Depletion  of  Immunoglobulin-Bearing Lymphocytes.--Two pooled  sensitized  Lewis  rat 
spleens were incubated with heat-inactivated rabbit antirat immunoglobulin  (Ig), prepared as 
previously described  (16, 17), at a final dilution of 1:10 for 30 rain at 37°C in the presence of 
a final 1  : 10 dilution of complement. DNase, 0.2 mg/ml, was then added for 10 rain  and the 
surviving cells were washed  twice. A 43%  reduction of the total cell population and total 
elimination of immunoglobulin-bearing  splenocytes, as determined by inspection  of suspen- 
sions incubated with FITC-conjugated rabbit antirat Ig (18), were achieved by this treatment. 
Quantitatlon of Lymphocyte Cyclic AMP Levds.--Triplicate or quadruplicate samples of 10 ~ 
sensitized Lewis spleen cells were maintained in Tyrode's buffer (2 cc/sample), exposed to the 
pharmacologic agent, and the intracellular levels of cyclic AMP quantitated at the same time 
that replicate cells were interacted with BN thymocytes. Cyclic AMP levels ranged from 0.55 
to 10 pmol (pM)/107 lymphocytes with an average  of 3.55 pM as determined by the cyclic 
AMP protein binding assay (19) as previously described (20). 
RESULTS 
Pharmacologic Augmentation of LMC.-- 
Cholinergic  stimulation: The previously observed effect of cholinergic agonists 
on LMC  (7) did not distinguish whether the action was upon the attacking or 
target cells. As shown in Fig. 1, the augmentation of LMC produced by carba- 
chol 10  -12 M  is completely dependent upon a  short period of preincubation of 
the  attacking  cells with  this  cholinergic agonist.  Augmentation  was  not  ob- 
served if the attacking cells were preincubated with carbachol for more than 6 
rain before introduction of the target cells, nor if the cholinomimetic was added 
after both  attacking and target cells were mixed. Even at  the higher concen- 
tration of  10  -l° M, the enhancement  was limited to a particular preincubation 
interval  (Table I),  and the magnitude was not greater than  that  with the les- 
ser dose. In the same  experiment,  10  -l° M  or 10  -'12 M  carbachol had  no  effect 
on  sensitized spleen cell cyclic AMP levels (Table I, Fig. 1). 
Cyclic GMP e~ects:  Cholinergic stimulation of several  tissues has been  as- 
sociated with tissue accumulation of cyclic GMP (8-13) ; therefore, the effect of 
exogenous 8-bromo-cyclic GMP upon LMC was studied. 8-bromo-cyclic GMP 
produced a  dose-dependent augmentation  of LMC  in  the  dose range of 5  X 
10  -6 to 1  X  10  -8 M  with a  maximum of 73 %  augmentation of LMC  (Fig. 2). 
The enhanced cytotoxicity induced by 8-bromo-cyclic GMP could not be pro- 
duced unless the agent was preincubated with the attacking cells, although the 
duration of preincubation was not as critical as in the carbachol experiments. 384  EFFECT  OF  CYCLIC  NUCLEOTIDES  IYL~ON LMC 
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TABLE I 
The Effect oJ Carbachol 10  -1° M  upon LMC and Lymphocyte  Cyclic AMP Levds 
Preincubation time  Augmentation LMC*  Cyclic AMP levels+* 
min  % 
0  0  1.94  ±  0.38 
2  3  (1-5)  2.02  ±  0.36 
4  27  (24-30)  1.93  ±  0.05 
6  5  (3-7)  1.85  ±  0.16 
10  1  (0-2)  1.97  ±  0.28 
* The average augmentation  of LMC  is noted with  the range of triplicate  samples en- 
closed in parentheses. 
~: The average cyclic AMP concentration in pM/107 lymphocytes is given ±  the standard 
error of the mean for triplicate samples. 
These  findings again indicate  that  8-bromo-cyclic GMP  was  acting on  the 
attacking rather  than the  target cell. Attention was  directed  to  determining 
whether  the  augmentation involved Ig-coated  (B)  lymphocytes as well as T 
lymphocytes. The deletion of Ig-coated cells had no effect on the capacity of 8- 
bromo-cyclic GMP to augment LMC  (Fig. 3). 
Imidazole  effects:  Imidazole, an agent known to stimulate cyclic AMP-phos- 
phodiesterase activity (21)  in broken cell preparations, is also capable of aug- STROM,  CARPENTER~  GAROVO¥,  ALISTEN~ MERRILL~  KALINER  385 
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FIG. 2. The effect of 8-bromo-cyclic  GMP upon LMC (range indicated by brackets). 
menting allograft-sensitized LMC  (22). The addition of 10  -7 M  imidazole to 
suspensions of attacking cells 2 rain before introduction of the target cells in- 
creased LMC by 50% in association with depletion of cyclic AMP levels from 
6.93 pM/107  lymphocytes to 3.97 pM/10  ~ (Fig. 4). Thus, imidazole-mediated 
enhancement is associated with changes not seen with cholinergic stimulation. 
Pharmacologic Attenuation of LMC.-- 
PGE1 effects: PGE1 (10  -4 M), an activator of lymphocyte adenylate cyclase 
(5), produced an increase in the level of cyclic AMP during the first 5 rain after 
introduction with a  maximal stimulation occurring after 1 h  of incubation at 
37°C and persisting for at least 2 h  (Fig. 5). The percent suppression of cyto- 
toxicity occurring after 1 h was not further increased after an additional hour. 
As the lymphocyte cyclic AMP level peaked 1 h after interaction with PGE1, 
a dose-response experiment was carried out utilizing a 60 rain preincubation of 
attacking cells and PGEI. Under these circumstances the dose-related inhibi- 
tion  of  LMC  included  one  concentration  (10  -6 M)  without  an  associated 
elevation of cyclic AMP (Fig. 6). That this dose of PGE1 was stimulating the 
adenylate cyclase in attacking cells is revealed in Fig. 7 in which the introduc- 
tion  of  the  phosphodiesterase-inhibiting  agent,  aminophyUine,  resulted  in  a 
synergistic accumulation of cyclic AMP and an additive suppression of LMC. 
Beta adrenergic stimulation: The beta adrenergic agonist, isoprotereno110-  5 M, 386  EFFECT OF  CYCLIC NUCLEOTIDES UPON LMC 
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was 38%. 
produced a modest inhibition of LMC without appreciably altering cyclic AMP 
levels when added to attacking cells 2 rain before mixing with target cells (Fig. 
8). The effect was not observed if interaction exceeded 2 min and could not be 
studied at higher concentrations of isoproterenol because of a direct toxic effect 
upon  the  target  cells.  The  combination  of  isoproterenol  and  aminophylline 
10  -3 M,  which  independently  suppressed  LMC  and  elevated  cyclic  AMP, 
caused an additive inhibition of LMC and a synergistic increase in intracellular 
cyclic AMP levels (Fig. 8). 
Cholera  toxin  effect:  In  order  to  establish  conclusively that  modulation  of 
LMC may result from an effect exclusively upon the attacking cell, experiments 
were carried out with cholera toxin, a prolonged activator of adenylate cyclase 
that can be removed after its interaction with the cell without loss of adenylate 
cyclase stimulation  (23).  Cholera toxin  (1/zg/ml)  was preincubated  with  sen- 
sitized  Lewis spleen  cells for 10,  30,  60,  120,  and  180 rain;  and  the cells were 
washed  three times before introduction  of target cells. The cyclic AMP levels 
were determined  at the time of introduction of the target cells.  Cholera toxin 
had little effect on either LMC or cyclic AMP levels until  180 rain of preincu- STROM~  CARPElqTER~  GAROVOY~ AUSTEN~  MERRILL~  KALINER  38~ 
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bation  when  both  a  marked  inhibition  of LMC  and  increase  in  cyclic AMP 
occurred (Fig. 9). 
DISCUSSION 
The capacity of allosensitized T  lymphocytes to destroy target cells bearing 
donor alloantigens is modulated by the cellular levels of cyclic AMP and cyclic 
GMP. Increases in attacking lymphocyte cyclic AMP levels, as achieved after 
stimulation  with PGE1, isoproterenol,  and cholera toxin, inhibit cytotoxicity; 
whereas, depletion of cyclic AMP with imidazole, cholinergic stimulation  with 
carbachol, or addition of 8-bromo-cyclic GMP enhance LMC. Chemically and 
pharmacologically distinct  agents  such as isoproterenol  (Fig.  8), PGE1  (Figs. 
5-7),  and  cholera  toxin  (Fig.  9)  having  in  common  the  ability  to  activate 
adenylate cyclase and thereby increase intracellular cyclic AMP, suppress LMC. 
Methylxanthines,  aminophylline  (Figs.  7 and 8) and  theophylline  (7), inhibit STROM,  CARPENTER~ GAROVOY~ AUSTEN,  MERRILL~ KALINER  389 
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phosphodiesterase protecting cyclic AMP  from breakdown,  and  also inhibit 
LMC. The combination of adenylate cyclase activators and methylxanthines 
produces an additive attenuation of LMC associated with a synergistic increase 
in cyclic AMP (Figs. 7 and 8).  Suppression of LMC is also  produced by di- 
butyryl cyclic AMP (7). Finally, the kinetic, inverse correlation between cyclic 
AMP levels and cytotoxicity  in a system in which the attacking cells exclusively 
have been treated with cholera toxin is the strongest evidence obtainable that 
elevations of attacking lymphocyte cyclic AMP suppress their ability to kill 
target cells  (Fig. 9).  The consistent inverse association between cyclic AMP 
levels  in  the  total  attacking  cell  population  and  modulation  of  target  cell 
destruction,  as  assessed  both  kinetically and  by  dose-response  stimulation 
employing chemically and pharmacologically distinct agents, suggests that the 
cyclic AMP levels in the total attacking lymphocyte population reflects that of 
the subpopulation of T lymphocytes actually involved in the cytotoxic process. 
In contrast, imidazole, an agent known to be capable of activating cyclic 
AMP phosphodiesterase (21) and herein demonstrated to deplete cyclic AMP 
concentrations, was found to enhance LMC (Fig. 4), suggesting that bidirec- 
tional alterations in cyclic AMP levels may influence LMC. Imidazole has been 390  EFFECT  OF  CYCLIC  NUCLEOTIDES  UPON  LMC 
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shown in  broken  cell  preparations  to  inhibit  cyclic  GMP phosphodiesterase 
(24),  an action capable of elevating cyclic GMP. Although the enhancement of 
LMC by imidazole may reflect both a depletion of cyclic AMP and an increase 
in cyclic GMP, it seems unlikely that the depletion of cyclic AMP is secondary 
to the rise of cyclic GMP  (25)  as cholinergic augmentation is not associated 
with a reduction of cyclic AMP concentration (Fig. 1, Table I). 
That cholinergic enhancement of LMC may be mediated through changes in 
the intracellular concentrations of cyclic GMP is suggested by the findings of 
others  that  cholinergic  stimulation  of  various  tissues  (8-13),  including  the 
human lymphocyte (13), transiently increases the levels of cyclic GMP and by 
the demonstration herein that exogenous 8-bromo-cyclie GMP enhances cyto- 
toxicity (Figs. 2 and 3). Furthermore, there is no change in c)~lic AMP levels 
after cholinergic stimulation  at  various  concentrations of carbachol over an 
incubation period of 10 rnin during which  time a  significant enhancement of 
LMC  was  appreciated  (Fig.  1,  Table I). These findings are comparable with 
studies of the immunologic release of chemical mediators from passively sensi- 
tized human lung fragments in which depletions of cyclic AMP after stimulation 
with  imidazole  or  alpha  adrenergic  agonists  augment  release,  while  similar 
enhancement after cholinergic stimulation occurs without a measurable change 
in cyclic AMP levels (20, 26). STROM, CARPENTER, GAROVOY, AUSTEN, MERRILL, KALINER  391 
In vitro LMC is dependent upon intimate contact (3) between viable lympho- 
cytes (1, 2) and target cells and is independent  of B lymphocytes (27), macro- 
phages (27, 28), antibody formation (29), and complement (3). Although direct 
measurement of cyclic AMP in the mouse lymphocyte-attacking cell population 
in previous investigations  has also revealed inhibition  of LMC in association 
with elevation of cyclic AMP, the attacking cell population was not purified to 
isolate a relatively homogeneous lymphoid population,  the agents were present 
throughout the period of attacking and target cell interaction  and  the  system 
did not reveal the enhancement operative in the present system (4-6). Selective 
destruction of immunoglobulin-bearing  (B) lymphocytes from sensitized spleen 
cell populations by pretreatment  with anti-Ig and C did not alter cytotoxicity 
nor  did  it  prevent  the  enhancement  of LMC  by  exogenous  8-bromo-cyclic 
GMP (Fig. 3). 
A brief preincubation of the attacking cell population with carbachol (Fig. 1) 
as well as 8-bromo-cyclic GMP (Fig. 2) before introduction  of the target cells 
is a prerequisite for cholinergic enhancement of LMC, an effect consistent with 
the known brief increases in cyclic GMP after cholinergic stimulation  (8-13). 
Furthermore, these data strongly suggest that cholinergic agents augment LMC 
via an effect upon the attacking cells alone, since the addition of carbachol  to at- 
tacking and target cell mixtures fails to enhance LMC. Similarly,  isoproterenol 
attenuates LMC only when the  attacking cells are briefly preincubated before 
entry of target cells into the mixture  (Fig. 8). These data and  the demonstra- 
tion that cholera  toxin-treated  (Fig.  9)  attacking  cells are  inhibited  in  their 
ability  to  injure  target cells only when cyclic AMP levels are  elevated at  the 
time of initial attacking-target  cell interaction  suggest  that  the level of cyclic 
nucleotide (cyclic AMP and cyclic GMP) within the attacking cells at the time 
of initial  contact  between the protagonist  cell populations  determines  largely 
the extent of cytotoxicity. 
SUMMARY 
The capacity of allosensitized thymus-derived lymphocytes to destroy target 
cells bearing  donor  alloantigens  is modulated  by the  cellular levels  of  cyclic 
AMP and cyclic GMP. Increases in the cyclic AMP levels of attacking lympho- 
cytes by stimulation  with prostaglandin  E1,  isoproterenol,  and  cholera  toxin 
inhibit  lymphocyte-mediated  cytotoxicity; whereas,  depletion of  cyclic  AMP 
with imidazole  enhances  cytotoxicity. The  augmentation  of  cytotoxicity pro- 
duced by cholinergic  stimulation  with carbamylcholine is not  associated  with 
alterations in cyclic AMP levels and is duplicated by 8-bromo-cyclic GMP. The 
effects of activators of adenylate cyclase, cholinomimetic agents,  and  8-bromo- 
cyclic GMP are upon the attacking  and not the target cells and occur  at  the 
time  of initial  interaction  of attacking  and  target  cells.  Indeed,  the  level  of 
cyclic nucleotide  (cyclic AMP and cyclic GMP)  at the time of  initial  cell-to- 
cell interaction determines the extent of cytotoxicity. 392  E~F17ECT  OF  CYCLIC  NUCLEOTIDES  UPON  L3/IC 
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